Cardiology discovery最新文献_第3页

Differential Roles of Interleukin-6 in Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Cardiometabolic Diseases. 白细胞介素-6在严重急性呼吸综合征-冠状病毒-2感染和心脏代谢疾病中的差异作用

Cardiology discovery Pub Date : 2023-09-01 Epub Date: 2023-07-27 DOI: 10.1097/CD9.0000000000000096

Jingjing Ren, Xiao-Qi Wang, Tetsushi Nakao, Peter Libby, Guo-Ping Shi

{"title":"Differential Roles of Interleukin-6 in Severe Acute Respiratory Syndrome-Coronavirus-2 Infection and Cardiometabolic Diseases.","authors":"Jingjing Ren, Xiao-Qi Wang, Tetsushi Nakao, Peter Libby, Guo-Ping Shi","doi":"10.1097/CD9.0000000000000096","DOIUrl":"10.1097/CD9.0000000000000096","url":null,"abstract":"<p><p>Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection can lead to a cytokine storm, unleashed in part by pyroptosis of virus-infected macrophages and monocytes. Interleukin-6 (IL-6) has emerged as a key participant in this ominous complication of COVID-19. IL-6 antagonists have improved outcomes in patients with COVID-19 in some, but not all, studies. IL-6 signaling involves at least 3 distinct pathways, including classic-signaling, trans-signaling, and trans-presentation depending on the localization of IL-6 receptor and its binding partner glycoprotein gp130. IL-6 has become a therapeutic target in COVID-19, cardiovascular diseases, and other inflammatory conditions. However, the efficacy of inhibition of IL-6 signaling in metabolic diseases, such as obesity and diabetes, may depend in part on cell type-dependent actions of IL-6 in controlling lipid metabolism, glucose uptake, and insulin sensitivity owing to complexities that remain to be elucidated. The present review sought to summarize and discuss the current understanding of how and whether targeting IL-6 signaling ameliorates outcomes following SARS-CoV-2 infection and associated clinical complications, focusing predominantly on metabolic and cardiovascular diseases.</p>","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":" ","pages":"166-182"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10750760/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48021226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ATP Stress Myocardial Contrast Echocardiography Assessment of Coronary Microvascular Disease with Spasmodic Characteristics: A Case Report ATP应激心肌对比超声心动图评估具有痉挛特征的冠状动脉微血管疾病1例

Cardiology discovery Pub Date : 2023-08-10 DOI: 10.1097/cd9.0000000000000099

Xuebing Liu, Chunmei Li

引用次数: 0

Regulation of Matrix Metalloproteinase-2 and Matrix Metalloproteinase-9 in Abdominal Aortic Aneurysm 基质金属蛋白酶-2和基质金属蛋白酶-9在腹主动脉瘤中的调控

Cardiology discovery Pub Date : 2023-07-27 DOI: 10.1097/cd9.0000000000000097

Shuo Wang, Dan Liu, Xiao-lin Zhang, X. Tian

引用次数: 0

Current Status of Left Atrial Appendage Thrombus with Atrial Fibrillation 左心房附件血栓合并心房颤动的现状

Cardiology discovery Pub Date : 2023-07-10 DOI: 10.1097/cd9.0000000000000095

Zhihong Zhao, Xingwei Zhang

引用次数: 0

Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study 尼可地尔和硝酸盐在中国中部冠心病患者中的主要不良心血管事件:一项回顾性队列研究

Cardiology discovery Pub Date : 2023-07-06 DOI: 10.1097/CD9.0000000000000092

Ping Li, Juan Chen, Na Li, X. You, Lan Shen, N. Zhou

{"title":"Real-World Major Adverse Cardiovascular Events of Nicorandil and Nitrate in Coronary Heart Disease in Central China: A Retrospective Cohort Study","authors":"Ping Li, Juan Chen, Na Li, X. You, Lan Shen, N. Zhou","doi":"10.1097/CD9.0000000000000092","DOIUrl":"https://doi.org/10.1097/CD9.0000000000000092","url":null,"abstract":"Objective: Residual cardiovascular risk in patients with coronary heart disease (CHD) still needs to be addressed in real-world practice. This study aimed to examine the clinical effectiveness of nicorandil and nitrate in addition to optimal treatment for CHD patients. Methods: This retrospective cohort study included patients with CHD between October 2009 and March 2020 from 2 tertiary hospitals in Wuhan, China. Patients were grouped into nicorandil and nitrate groups depending on the first recorded antianginal therapy. Demographic and clinical data were collected from databases of the 2 hospitals. The primary outcome was cumulative 18-month major adverse cardiovascular event (MACE)-free survival, which was evaluated by Kaplan-Meier analysis. Propensity score matching (PSM) and multivariate Cox regression were adopted to adjust for confounding factors. Results: A total of 14,275 patients were analyzed, including 590 and 13,685 patients in the nicorandil and nitrate groups, respectively. With a median follow-up of 0.88 (Q1, Q3: 0.21, 1.54) years, the cumulative 18-month MACE-free survival rates were comparable between the 2 groups (80.0% vs. 75.0%, adjusted hazard ratio (aHR): 1.04, 95% confidence interval (CI): 0.42–2.56, P = 0.982,7) after 1:4 PSM. The cumulative 18-month stroke-free survival rate was significantly higher in the nicorandil group compared to the nitrate group (93.0% vs. 84.0%, aHR: 0.56, 95% CI: 0.34–0.92, P = 0.023,5). Conclusion: This retrospective study showed that nicorandil and nitrate have similar 18-month rates of MACEs in CHD patients, but nicorandil is associated with lower incidence of stroke compared to nitrate. More studies need to be conducted to validate this association and explore the long-term benefit of nicorandil use on the occurrence of MACEs in the future.","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":"3 1","pages":"152 - 158"},"PeriodicalIF":0.0,"publicationDate":"2023-07-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44240256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utilization of Transthoracic Echocardiography Is Associated with a Decreased 6-month Readmission Rate in Hospitalized Heart Failure: A Propensity Score-matched Analysis 经胸超声心动图的应用与住院心力衰竭患者6个月复查率降低相关：倾向性评分匹配分析

Cardiology discovery Pub Date : 2023-07-04 DOI: 10.1097/CD9.0000000000000093

Zhiqing Fu, Shan Li, Xiaoning Zhao, Qiang Wang

{"title":"Utilization of Transthoracic Echocardiography Is Associated with a Decreased 6-month Readmission Rate in Hospitalized Heart Failure: A Propensity Score-matched Analysis","authors":"Zhiqing Fu, Shan Li, Xiaoning Zhao, Qiang Wang","doi":"10.1097/CD9.0000000000000093","DOIUrl":"https://doi.org/10.1097/CD9.0000000000000093","url":null,"abstract":"Objective: Repeated hospitalization due to congestion is a characteristic of the whole course of heart failure. Echocardiography can be used to assess cardiac function and volume status. However, whether echocardiography can reduce the rehospitalization rate remains unclear. This study aimed to evaluate the impact of transthoracic echocardiography (TTE) use on readmission rates in hospitalized patients with heart failure. Methods: The study was based on the Zigong heart failure database, which contained information on 2,008 adult patients with heart failure admitted to the Zigong Fourth People’s Hospital (Sichuan Province, China) from December 2016 to June 2019. Patients were divided into 2 groups according to the usage of TTE on the day of hospital admission (TTE group (1,371 patients) and no TTE group (637 patients), respectively). The primary outcome was the 6-month readmission rate. The statistical approaches used included multivariate Cox regression, propensity score analysis, and an inverse probability weighting model to ensure the robustness of the findings. Results: A significant reduction in 6-month readmission rate was observed among the TTE group compared with the no TTE group (hazard ratio = 0.60, 95% confidence interval (CI) = 0.52–0.69, P < 0.001). The frequencies of intravenous nitrates, diuretics, and inotropes during hospitalization were significantly higher in the TTE group compared with those in the no TTE group (10.9% vs. 8.3%, 88.5% vs. 86.2%, and 66.9% vs. 65.6%, respectively, all P < 0.001). The proportion of patients returning to the emergency department within 6 months was significantly lower in the TTE group compared with the no TTE group (35.6% vs. 50.3%, P < 0.001). Conclusions: Utilization of TEE on admission day was associated with a reduced 6-month readmission rate in hospitalized patients with heart failure.","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":"3 1","pages":"145 - 151"},"PeriodicalIF":0.0,"publicationDate":"2023-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42666536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Surgical treatment of left atrial dissection and severe mitral valve obstruction 纠正:左心房夹层合并严重二尖瓣梗阻的手术治疗

Cardiology discovery Pub Date : 2023-06-29 DOI: 10.1097/cd9.0000000000000098

引用次数: 0

The Construction of an Intrauterine Diagnosis and Treatment System and Comprehensive Lifecycle Health Service of Congenital Heart Disease: Xinhua Hospital Model 先天性心脏病宫内诊疗体系构建与全生命周期健康服务——新华医院模式

Cardiology discovery Pub Date : 2023-06-28 DOI: 10.1097/cd9.0000000000000089

Shiwei Jiang, Jiajun Ye, Hualin Wang, Jian Wang, Sun Chen, Yongjun Zhang, Q. Du, Ling Yang, Lei Wang, K. Sun

引用次数: 0

Yangxinshi Tablets Versus Trimetazidine on Exercise Tolerance After Percutaneous Coronary Intervention: Rationale and Design of the Double-blind, Randomized HEARTRIP Trial 养心石片与曲美他嗪对经皮冠状动脉介入治疗后运动耐量的影响:双盲、随机心脏trip试验的基本原理和设计

Cardiology discovery Pub Date : 2023-06-01 DOI: 10.1097/cd9.0000000000000094

Yi Li, Jian Zhang, Hong Chen, Yi Zhang, Jing Li, Haichu Yu, X. Meng, Haitao Yuan, Lili Shao, Yaling Han

引用次数: 0

Bioinformatics Analysis of the Regulatory lncRNA–miRNA–mRNA Network and Drug Prediction in Patients with Pulmonary Arterial Hypertension 肺动脉高压患者lncRNA-miRNA-mRNA调控网络的生物信息学分析及药物预测

Cardiology discovery Pub Date : 2023-06-01 DOI: 10.1097/CD9.0000000000000091

Xiao Jin, Ling Jin, Li Han, Shiping Zhu

{"title":"Bioinformatics Analysis of the Regulatory lncRNA–miRNA–mRNA Network and Drug Prediction in Patients with Pulmonary Arterial Hypertension","authors":"Xiao Jin, Ling Jin, Li Han, Shiping Zhu","doi":"10.1097/CD9.0000000000000091","DOIUrl":"https://doi.org/10.1097/CD9.0000000000000091","url":null,"abstract":"Objective: Pulmonary arterial hypertension (PAH) is a cardiovascular disease caused by primary proliferative lesions in pulmonary arterioles. Competing endogenous RNAs (ceRNAs) have been reported to act as sponges for microRNAs (miRNAs). To date, however, the mechanisms underlying ceRNA involvement in PAH have not been investigated. This study aimed to construct a PAH-related ceRNA network to further explore the mechanisms of PAH. Methods: A probe reannotation was conducted to identify the long non-coding RNAs (lncRNAs) and messenger RNAs (mRNAs) involved in PAH. Based on the reannotation results, the “limma” package was used to identify the differentially expressed genes (DEGs) and lncRNAs. The miRcode database was used to predict the lncRNA–miRNA interactions. Then, the mRNAs targeted by the miRNAs were predicted by using TargetScan, miRTarBase, and miRDB. Based on the above interactions, a ceRNA network was constructed, which was mapped and visualized with Cytoscape 3.6.1 software. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analyses were performed using the database. To predict possible drugs or molecules that may mitigate PAH, C-Map analysis was applied to find relevant molecular compounds that can reverse the expression of DEGs in cell lines. Results: The ceRNA network consisted of 174 nodes and 304 links, which included 10 lncRNAs, 23 miRNAs, and 53 mRNAs. The hub genes of the ceRNA network for PAH included hsa-miR-17-5p, hsa-miR-20b-5p, MEG3, HCP5, hsa-miR-27a-3p, hsa-miR-107, hsa-miR-142-3p, hsa-miR-363-3p, hsa-miR-301b-3p, and hsa-miR-23b-3p. Calprotectin, irinotecan, and medrysone were found to be the 3 significant compounds. Conclusion: This study found that hsa-miR-17-5p, hsa-miR-20b-5p, MEG3, HCP5, hsa-miR-27a-3p, hsa-miR-107, hsa-miR-142-3p, hsa-miR-363-3p, hsa-miR-301b-3p, and hsa-miR-23b-3p maybe the underlying biomarkers and targets for diagnosis and treatment of PAH.","PeriodicalId":72524,"journal":{"name":"Cardiology discovery","volume":"3 1","pages":"85 - 94"},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45068554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0